Evidence map›Paper›PMID 39815057›Full record

ArticleMolecular psychiatry2025

Choroid plexus volume is enlarged in long COVID and associated with cognitive and brain changes.

Maria Diez-Cirarda, Miguel Yus-Fuertes, Cristina Delgado-Alonso, Lidia Gil-Martínez, Carlos Jiménez-García, Maria José Gil-Moreno, Natividad Gómez-Ruiz, Silvia Oliver-Mas, Carmen Polidura, Manuela Jorquera and 6 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Human brain matters: Navigating the neuropathology of COVID-19.Brain pathology (Zurich, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maria Diez-CirardaDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain. mdcirarda@salud.madrid.org.ORCID 0000-0001-6768-189X
Miguel Yus-FuertesDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.ORCID 0000-0003-3191-6743
Cristina Delgado-AlonsoDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Lidia Gil-MartínezDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.ORCID 0000-0002-9547-5038
Carlos Jiménez-GarcíaDepartment of Immunology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Maria José Gil-MorenoDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Natividad Gómez-RuizDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Silvia Oliver-MasDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Carmen PoliduraDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Manuela JorqueraDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Ulises Gómez-PinedoDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Juan ArrazolaDepartment of Radiology, Hospital Universitario Clinico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Silvia Sánchez-RamónDepartment of Immunology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Jorge Matias-GuiuDepartment of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain.
Gabriel Gonzalez-Escamilla *Department of Neurology, Focus Program Translational Neuroscience (FTN), University Medical Center of the Johannes Gutenberg, University Mainz, Mainz, Germany.ORCID 0000-0002-7209-1736
Jordi A Matias-Guiu *Department of Neurology, Hospital Universitario Clínico San Carlos. Health Research Institute "San Carlos" (IdISCC). Universidad Complutense de Madrid, Madrid, Spain. jordi.matias-guiu@salud.madrid.org.ORCID 0000-0001-5520-2708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with post-COVID condition (PCC) present with diverse symptoms which persist at long-term after SARS-CoV-2 infection. Among these symptoms, cognitive impairment is one of the most prevalent and has been related to brain structural and functional changes. The underlying mechanisms of these cognitive and brain alterations remain elusive but neuroinflammation and immune mechanisms have been majorly considered. In this sense, the choroid plexus (ChP) volume has been proposed as a marker of neuroinflammation in immune-mediated conditions and the ChP epithelium has been found particularly susceptible to the effects of SARS-CoV-2. The objective was to investigate the ChP in PCC and evaluate its relationships with cognition, brain, and immunological alterations. One-hundred and twenty-nine patients with PCC after a mean of 14.79 ± 7.17 months of evolution since the infection and 36 healthy controls were recruited. Participants underwent a neuropsychological, and neuroimaging assessment and immunological markers evaluation. Results revealed ChP volume enlargement in PCC compared to healthy controls. The ChP enlargement was associated with cognitive dysfunction, grey matter volume reduction in frontal and subcortical areas, white matter integrity and diffusivity changes and functional connectivity changes. These ChP changes were also related to intermediate monocytes levels. Findings suggest that the ChP integrity may play a relevant role in the pathophysiology of cognitive deficits and the observed brain changes in PCC. The previously documented function of the ChP in maintaining brain homeostasis and regulating the entry of immune cells into the brain supports the presence of neuroinflammatory mechanisms in this disorder.

Indexed as

BrainChoroid PlexusCognitive DysfunctionCOVID-19AdultAgedCognitionFemaleGray MatterHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsOrgan SizeSARS-CoV-2

Identifiers

PMID39815057
PMCPMC12185318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.